

DAFTAR PUSTAKA

- Alex, K., Tillack, A., Schwarz, N., & Beller, M., 2008, Zinc-catalyzed synthesis of pyrazolines and pyrazoles via hydrohydrazination, *Org. Lett.* **10(12)**, 2377–2379.
- Ananda, H., Sharath Kumar, K. S., Sudhanva, M. S., Rangappa, S., & Rangappa, Ardiansyah, B., 2017, Pharmaceutical importance of pyrazoline derivatives: A mini review, *J. Pharm Sci. Res.* **9**, 1958–1960.
- Atlas, S., Saalim, M., Bhupesu, K. V., & Prasad, K., 2014, Anticonvulsant and antidepressant activity studies of synthesized some new 1, 3, 5-trisubstituted-2-pyrazolines, *Int. J. PharmTech Res.* **6**, 1113–1123.
- Baur, F., Beattie, D., Beer, D., Bentley, D., Bradley, M., Bruce, I., Wyss, D., 2010, The Identification of Indacaterol as an Ultralong-Acting Inhaled β_2 -Adrenoreceptor Agonist, *J. Med. Chem.*, **53(9)**, 3675–3684.
- Bonfield, K., Amato, E., Bankemper, T., Agard, H., Steller, J., Keeler, J. M., Roy, D., McCallum, A., Paula, S., & Ma, L., 2012, Development of a new class of aromatase inhibitors: Design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives, *Bioorg Med. Chem.* **20(8)**, 2603–2613.
- Borah, P., Shivling, V. D., Banik, B. K., & Sahoo, B. M., 2020, An Overview on Steroids and Microwave Energy in Multi-Component Reactions towards the Synthesis of Novel Hybrid Molecules, *Curr. Org. Synth.*, **17(8)**, 594–609.
- Chin, W. W., 1998. The Partial Least Squares Approach to Structural Equation Modeling. *Modern Methods for Business Research*, 295, 336.
- Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A., 2011, Aromatase, Aromatase Inhibitors, and Breast Cancer, *J. Steroid Biochem. Mol. Biol.* **125(1–2)**, 13–22.
- Cichero, E., dan Fossa, P., 2011, Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitor, *J. Mol. Model.* **18(4)**, 1573–1582.
- Cui, J., Shen, Y., & Li, R., 2013, Estrogen synthesis and signaling pathways during ageing: From periphery to brain, *Trends Mol. Med.* **19(3)**, 197–209.
- Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S., 2020, Discovering Anti-Cancer Drugs via Computational Methods, *Front. Pharmacol.* **11**, 733.
- Dinesha, null, Viveka, S., Priya, B. K., Pai, K. S. R., Naveen, S., Lokanath, N. K., & Nagaraja, G. K., 2015, Synthesis and pharmacological evaluation of some new fluorine containing hydroxypyrazolines as potential anticancer and antioxidant agents, *Eur. J. Med. Chem.* **104**, 25–32.
- Doiron, J., Saultan, A. H., Richard, R., Touré, M. M., Picot, N., Richard, R., Čuperlović-Culf, M., Robichaud, G. A., & Touaibia, M., 2011, Synthesis and structure–activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors, *Eur. J. Med. Chem.*, **46(9)**, 4010–4024.

- Du, X., Li, Y., Xia, Y. L., Ai, S. M., Liang, J., Sang, P., Ji, X. L., & Liu, S. Q., 2016, Insights into Protein-Ligand Interactions: Mechanisms, Models, and Methods, *Int. J. Mol. Sci.* **17**(2), E144.
- Ethiraj, K. R., Nithya, P., Krishnakumar, V., Jesil Mathew, A., & Nawaz Khan, F. 2013, Synthesis and cytotoxicity study of pyrazoline derivatives of methoxy substituted naphthyl chalcones, *Res. Chem. Intermed.* **39**(4), 1833–1841.
- Ferreira, L. G., Dos Santos, R. N., Oliva, G., & Andricopulo, A. D., 2015, Molecular docking and structure-based drug design strategies, *Molecules* **20**(7), 13384–13421.
- Ghosh, D., Griswold, J., Erman, M., & Pangborn, W., 2009, Structural basis for androgen specificity and oestrogen synthesis in human aromatase, *Nature* **457**(7226), 219–223.
- Ghosh, D., Griswold, J., Erman, M., & Pangborn, W., 2010, X-ray Structure of Human Aromatase Reveals An Androgen-Specific Active Site, *J. Steroid Biochem. Mol. Biol.* **118**(4–5), 197–202.
- Gomes, P. M. O., Ouro, P. M. S., Silva, A. M. S., & Silva, V. L. M., 2020, Styrylpyrazoles: Properties, Synthesis and Transformations, *Molecules* **25**(24), 5886.
- Gürdere, M. B., Gümüş, O., Yaglioglu, A. S., Budak, Y., & Ceylan, M., 2017, Synthesis and anticancer activities of 1,4-phenylene-bis-N-acetyl- and N-phenylpyrazoline derivatives, *Res. Chem. Intermed.* **43**(3), 1277–1289.
- Hägström, Mikael., 2014, Medical gallery of Mikael Häggström 2014, Wikiversity Journal of Medicine, 1, 10.15347/wjm/2014.008.
- Haider, K., Shafeeqe, M., Yahya, S., & Yar, M. S., 2022, A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents, *Eur. J. Med. Chem.* **5**, 100042.
- Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia, M. M., 2020, Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study, *Lancet Glob. Health* **8**(8), e1027–e1037.
- Hevener, K. E., Zhao, W., Ball, D. M., Babaoglu, K., Qi, J., White, S. W., & Lee, R. E., 2009, Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase, *J. Chem. Inf. Mod.* **49**(2), 444–460.
- IARC, 2020, Cancer today. <http://gco.iarc.fr/today/home>, 15 Maret 2022.
- Jänicke, F., 2004, Are all aromatase inhibitors the same? A review of the current evidence, *The Breast* **13**(1), 10–18.
- Johnson, M., 2006, Molecular mechanisms of β 2-adrenergic receptor function, response, and regulation, *J. Allergy Clin. Immunol.*, **117**(1), 18–24.
- Karad, S. C., Purohit, V. B., Thakor, P., Thakkar, V. R., & Raval, D. K., 2016, Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities, *Eur. J. Med. Chem.* **112**, 270–279.
- Kitchen, D. B., Decornez, H., Furr, John R., & Bajorath, J., 2004, Docking and Scoring in Virtual Screening for Drug Discovery: Methods and Applications, *Nat. Rev.* **3**, 935–949.

- Kumar, K., & Govindaraju, M., 2015, Pyrazolines: Versatile Molecules of Synthetic and Pharmaceutical Applications-A Review, *Int. J. Chemtech Res.* **8**, 313–322.
- Mantas, D., Kostakis, J. D., & Markopoulos, C., 2016, Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients, *Hellenic J. Surg.* **88**(4), 245–251.
- Matiadis, D., & Sagnou, M., 2020, Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview, *Int. J. Mol. Sci.* **21**(15), 5507.
- Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M., 2011, Molecular docking: A powerful approach for structure-based drug discovery, *Curr. Comp-Aided Drug Des.* **7**(2), 146–157.
- Miller, W. L., & Auchus, R. J., 2011, The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders, *Endocr Rev.* **32**(1), 81–151.
- Payne, A. H., & Hales, D. B., 2004, Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones, *Endocr Rev.* **25**(6), 947–970.
- Rashdan, H. R. M., & Shehadi, I. A., 2022, Triazoles Synthesis & Applications as Nonsteroidal Aromatase Inhibitors for Hormone-Dependent Breast Cancer Treatment, *Heteroat. Chem.* **2022**, e5349279.
- Rj, S., H, B., Er, S., Pk, S., & A, B., 2009, History of aromatase: Saga of an important biological mediator and therapeutic target, *Endocr Rev.* **30**(4), 343–375.
- Rugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., Johnston, S. R. D., Korde, L. A., Khatcheressian, J. L., Mehta, R. S., Muss, H. B., & Burstein, H. J., 2016, Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer, *J. Clin. Oncol.* **34**(25), 3069–3103.
- Safaei, S., Mohammadpoor-Baltork, I., Khosropour, A. R., Moghadam, M., Tangestaninejad, S., & Mirkhani, V., 2012, Diastereoselective Synthesis of Pyrazolines using a Bifunctional Brønsted Acidic Ionic Liquid under Solvent-Free Conditions, *Adv. Synth. Catal.* **354**(16), 3095–3104.
- Schiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H., 2019, Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review, *J. Steroid Biochem. Mol. Biol.* **194**, 105439.
- Sharma, M., Sharma, S., Buddhiraja, A., Saxena, A. K., Nepali, K., & Bedi, P. M. S., 2014, Synthesis and cytotoxicity studies of 3,5-diaryl N-acetyl pyrazoline—Isatin hybrids, *Med. Chem. Res.* **23**(10), 4337–4344.
- Singh, G., Goyal, A., Bhatti, R., & Arora, S., 2017, Drugs With Pyrazoline Nucleus In Market (Short Communication), *Eng. Sci. Technol. an Int.* **6**, 73–78.
- Suvannang, N., Nantasenamat, C., Isarankura-Na-Ayudhya, C., & Prachayasittikul, V., 2011, Molecular Docking of Aromatase Inhibitors, *Molecules* **16**(5), 3597–3617.

- Theresih, K., & Budimarwanti, C., 2016, Pengaruh Gugus P-Metoksi Pada Reaksi Kondensasi Claysen-Schmidt Menggunakan Metoda Grinding, *Jurnal Sains Dasar* **5(2)**, 124–132.
- Vahedpour, T., Hamzeh-Mivehroud, M., Hemmati, S., & Dastmalchi, S., 2021, Synthesis of 2-Pyrazolines from Hydrazines: Mechanisms Explained, *ChemistrySelect* **6(25)**, 6483–6506.
- Varghese, B., Al-Busafi, S. N., Suliman, F. O., & Al-Kindy, S. M. Z., 2017, Unveiling a versatile heterocycle: Pyrazoline-a review, *RSC Advances* **7(74)**, 46999–47016.
- Viveka, S., Dinesha, null, Shama, P., Nagaraja, G. K., Ballav, S., & Kerkar, S., 2015, Design and synthesis of some new pyrazolyl-pyrazolines as potential anti-inflammatory, analgesic and antibacterial agents, *Eur. J. Med. Chem.* **101**, 442–451.
- Wahyuningsih, T. D., & Suma, A. A. T., 2019, Synthesis, anticancer activity, and docking study of N-acetyl pyrazolines from veratraldehyde, *J. Anim. Plant. Sci.* **9(3)**, 14–20.
- Watkins, E. J., 2019, Overview of breast cancer, *JAAPA* **32(10)**, 13–17.
- Wermuth, C. G., Ganellin, C. R., Lindberg, P., & Mitscher, I. A., 1998, Glossary of Terms Used in Medicinal Chemistry, 1129-1143, IUPAC, Great Britain.
- Wijaya, D. P., 2015, Optimasi Perbandingan Starting Material Pada Sintesis Senyawa Antikanker Gamavuton-0 (GVT-0) Menggunakan Regresi Polinomial Orde 2, Thesis, Fakultas Kedokteran Dan Ilmu Kesehatan Universitas Muhammadiyah Yogyakarta, Yogyakarta.
- Wu, X. F., Neumann, H., & Beller, M., 2011, A Straightforward Synthesis of Pyrazolines and Pyrazoles: Palladium-Catalyzed Carbonylative Vinylation–Cyclocondensation Reactions of Aryl Halides, *Eur. J. Org. Chem.* **2011(25)**, 4919–4924.
- Yamamoto, M., Hosoda, M., Nakano, K., Jia, S., Hatanaka, K. C., Takakuwa, E., Hatanaka, Y., Matsuno, Y., & Yamashita, H., 2014, P53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors, *Cancer Science* **105(1)**, 81–88.
- Yang, S. Y., 2010, Pharmacophore modeling and applications in drug discovery: Challenges and recent advances, *Drug Discov.* **15(11–12)**, 444–450.
- Yoshimoto, F. K., & Guengerich, F. P., 2014, Mechanism of the Third Oxidative Step in the Conversion of Androgens to Estrogens by Cytochrome P450 19A1 Steroid Aromatase, *J. Am. Chem. Soc.* **136 (42)**, 15016–15025.
- Young, D.C., 2001, Computation Chemistry: Pratical Guide for Applying Techniques to Real-World Problem, John Wiley & Sons, Inc., New York.
- Zhang, D. Y., Shao, L., Xu, J., & Hu, X.-P., 2015, Copper-Catalyzed Asymmetric Formal [3 + 2] Cycloaddition of Propargylic Acetates with Hydrazines: Enantioselective Synthesis of Optically Active 2-Pyrazolines, *ACS Catalysis* **5(9)**, 5026–5030.
- Zhao, H., Zhou, L., Shangguan, A. J., & Bulun, S. E., 2016, Aromatase expression and regulation in breast and endometrial cancer, *J. Mol. Endocrinol.* **57(1)**, R19–R33.